secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0000950170-24-036135
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics reports 2023 revenue $113.5M, net loss $85.5M; ETUARY sales up 13%
--------------------------------------------------------------------------------

- Full year 2023 revenue of $113.5M, up from $102.3M in 2022; net loss of $85.5M vs net income of $4.3M in 2022.
- ETUARY sales reached $112.1M in 2023, a 13% increase; sales team covers 35,512 hospitals across PRC.
- Cash and cash equivalents $33.5M as of Dec 31, 2023 vs $25.2M end of 2022.
- Phase 3 trial for F351 in CHB-associated liver fibrosis topline data expected by early 2025; U.S. Phase 2a in NASH planned for 2025.
- Appointed Han Ying as CEO in January 2024; completed business combination with GNI in October 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000095017024036135/0000950170-24-036135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000095017024036135/gyre-20240326.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-036135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer